Stockholm aims at becoming one of the world’s top life science regions

Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world’s top 5 regions in life science by 20...

Bioarctic gör flera tunga rekryteringar: "Tid att växla upp"

Bioarctic, som utvecklar en behandling mot Alzheimers sjukdom, gör flera rekryteringar inför en kommande ansökan om marknadsgodkännande. – Bioarctic tar nu det ...

IVI’s Director General on establishing in Sweden: Will need up to 40 employees

The International Vaccine Institute, IVI, hopes to have its first staff on-site in Stockholm within a couple of months, says the institute’s Director General Je...

Automated opening and closing of sample vials

From technical requirements to a suitable solution

Calliditas beviljas prioriterad granskning

Calliditas läkemedel Nefecon mot Bergers sjukdom kan bli godkänt av FDA i september.

Product Specialist at Gradientech AB, Uppsala

Hon tar plats på Bactiguard

Petra Kaur Ljungman tillträder den nyinrättade rollen som global marknads- och kommunikationschef.

Marie Gårdmark: New incentives for orphan products on its way

"Let’s hope that the learnings from development of new therapies for rare diseases will spill over to more common conditions, orphan products paving the wave fo...

Giulia Gaudenzi: ”Key lessons from global health research”

The world will still face major challenges in the post Covid-19 pandemic, writes Giulia Gaudenzi at the KTH Division of Nanobiotechnology at Scilifelab, in a column.

Nordic Regulatory experts: Improving biotech chances of Succ

Why is it that so many biotech companies fail? And what are the tools needed to change that fact?

Marie Gårdmark: Finally, it’s time for a revision of the EU pharma legislation

A challenge for the EU Commission is to deliver a new framework that will also take care of another “pillar” of the pharmaceutical strategy, namely, to ensure t...

Bought a tablet factory – and built his own empire

In 1995, Thomas Eldered was CEO of one of Pharmacia’s factories in the Stockholm area when the Swedish pharmaceutical giant, after a takeover, decided to move i...

Oncopeptides har ansökt om tillstånd för kliniska studier i USA

Oncopeptides planerar att påbörja kliniska studier i USA med deras andra läkemedelskandidat för patienter med multipelt myelom.

New influenza vaccine to EU

The Astrazeneca subsidary Medimmune submits marketing authorisationapplication in EU for an new intranasal vaccine against influenza.

Bactiguard stärker upp operations

Rekryterar VP direkt från Pfizer.

Anställer affärsutvecklare

Bioteknikbolaget Acousort har anställt Kristian Enqvist som affärsutvecklingschef på konsultbasis.

Anställer affärsutvecklare

Bioteknikbolaget Acousort har anställt Kristian Enqvist som affärsutvecklingschef på konsultbasis.

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct s...

Genovis i kontrakt med megabolag

Ska utveckla analys av biologiska läkemedel.

Marie Gårdmark: Big data evidence generation drives change in the EU regulatory system

Rapid developments in technology have led to the possibility for the generation and analysis of vast volumes of data. Will the availability of big data lead to ...

Första behandlingen mot ebola på väg

CHMP rekommenderar godkännande av vaccinet Ervebo för förebyggande behandling mot ebolainfektion.

Nytt partnerskap för Bactiguard

Bolaget ingår partnerskap med en schweizisk distributör som kommer att hantera hela Bactiguards infektionsförbyggande portfölj.

When carelessness, forgetfulness and coincidence become the researcher’s best friend

Forgetfulness, coincidence and a stroke of luck hardly make up a fruitful method of serious research. Or do they? Actually, a number of important medical advanc...

Column: Repurposing as a golden ticket to approval

"Hopefully, in the end, patients will be winners by receiving on-label treatments for which benefit-risk has been properly assessed." In a column Marie Gårdmark...